Related references
Note: Only part of the references are listed.HPF1 completes the PARP active site for DNA damage-induced ADP-ribosylation
Marcin J. Suskiewicz et al.
NATURE (2020)
Structural basis for allosteric PARP-1 retention on DNA breaks
Levani Zandarashvili et al.
SCIENCE (2020)
Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo
Zhengping Shao et al.
NUCLEIC ACIDS RESEARCH (2020)
The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment
Szilvia Juhasz et al.
SCIENCE ADVANCES (2020)
Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity
Hua-Dong Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2019)
Advances and perspectives of PARP inhibitors
Ming Yi et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)
A rapid fluorescent method for the real-time measurement of poly(ADP-ribose) polymerase 1 activity
T. A. Kurgina et al.
ANALYTICAL BIOCHEMISTRY (2018)
Serine is the major residue for ADP-ribosylation upon DNA damage
Luca Palazzo et al.
ELIFE (2018)
Poly(ADP-ribose) polymerase 1 searches DNA via a 'monkey bar' mechanism
Johannes Rudolph et al.
ELIFE (2018)
PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification
Marie-France Langelier et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2018)
Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease
Tae-In Kam et al.
SCIENCE (2018)
Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases
Nathan A. Berger et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
Ann-Gerd Thorsell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Serine ADP-Ribosylation Depends on HPF1
Juan Jose Bonfiglio et al.
MOLECULAR CELL (2017)
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Arnab Ray Chaudhuri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
Readers of poly(ADP-ribose): designed to be fit for purpose
Federico Teloni et al.
NUCLEIC ACIDS RESEARCH (2016)
HPF1/C4orf27 Is a PARP-1-Interacting Protein that Regulates PARP-1 ADP-Ribosylation Activity
Ian Gibbs-Seymour et al.
MOLECULAR CELL (2016)
New Facets in the Regulation of Gene Expression by ADP-Ribosylation and Poly(ADP-ribose) Polymerases
Keun Woo Ryu et al.
CHEMICAL REVIEWS (2015)
Mechanistic Dissection of PARP1 Trapping and the Impacton In Vivo Tolerability and Efficacy of PARP Inhibitors
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2015)
PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain
Jennine M. Dawicki-McKenna et al.
MOLECULAR CELL (2015)
Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases
Julio C. Morales et al.
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION (2014)
3D Flexible Alignment Using 2D Maximum Common Substructure: Dependence of Prediction Accuracy on Target-Reference Chemical Similarity
Takeshi Kawabata et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
Downfall of Iniparib: A PARP Inhibitor That Doesn't Inhibit PARP After All
Gunjan Sinha
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
Christopher P. Irwin et al.
NEOPLASIA (2014)
BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
Yuqiao Shen et al.
CLINICAL CANCER RESEARCH (2013)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Alternative Modes of Binding of Poly(ADP-ribose) Polymerase 1 to Free DNA and Nucleosomes
Nicholas J. Clark et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Fluorescence strategies for high-throughput quantification of protein interactions
Aaron R. Hieb et al.
NUCLEIC ACIDS RESEARCH (2012)
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Anand G. Patel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Opinion - Drug-target residence time and its implications for lead optimization
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse
JMN de Murcia et al.
EMBO JOURNAL (2003)
Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1
V Schreiber et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
